CCDC82

Summary

CCDC82 (coiled-coil domain containing 82, HGNC:26282) is a protein-coding gene on chromosome 11q21, encoding Coiled-coil domain-containing protein 82 (Q8N4S0).

Predicted to be active in nucleus.

Source: NCBI Gene 79780 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 107 total — 1 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_024725

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26282
Approved symbol	CCDC82
Name	coiled-coil domain containing 82
Location	11q21
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23518
Ensembl gene	ENSG00000149231
Ensembl biotype	protein_coding
OMIM	619870
Entrez	79780

Gene structure

Transcript identifiers

Ensembl transcripts: 84 — 69 protein_coding, 11 retained_intron, 4 protein_coding_CDS_not_defined

ENST00000278520, ENST00000423339, ENST00000524836, ENST00000525786, ENST00000530106, ENST00000530203, ENST00000538597, ENST00000545264, ENST00000643839, ENST00000644312, ENST00000644686, ENST00000645302, ENST00000645366, ENST00000645439, ENST00000645500, ENST00000646050, ENST00000646638, ENST00000646818, ENST00000647080, ENST00000647522, ENST00000679577, ENST00000679616, ENST00000679696, ENST00000679708, ENST00000679788, ENST00000679823, ENST00000679856, ENST00000679960, ENST00000680049, ENST00000680052, ENST00000680171, ENST00000680322, ENST00000680334, ENST00000680532, ENST00000680728, ENST00000680763, ENST00000680859, ENST00000680979, ENST00000681014, ENST00000681164, ENST00000681200, ENST00000681238, ENST00000681451, ENST00000681745, ENST00000681868, ENST00000681899, ENST00000907426, ENST00000907427, ENST00000907428, ENST00000907429, ENST00000907430, ENST00000907431, ENST00000907432, ENST00000907433, ENST00000907434, ENST00000907435, ENST00000907436, ENST00000907437, ENST00000907438, ENST00000907439, ENST00000907440, ENST00000907441, ENST00000926607, ENST00000926608, ENST00000926609, ENST00000926610, ENST00000926611, ENST00000926612, ENST00000926613, ENST00000926614, ENST00000926615, ENST00000926616, ENST00000926617, ENST00000926618, ENST00000926619, ENST00000926620, ENST00000926621, ENST00000926622, ENST00000946084, ENST00000946085, ENST00000946086, ENST00000946087, ENST00000946088, ENST00000946089

RefSeq mRNA: 4 — MANE Select: NM_024725 NM_001318736, NM_001318737, NM_001363594, NM_024725

CCDS: CCDS8307, CCDS86241, CCDS86243

Canonical transcript exons

ENST00000646818 — 10 exons

Exon	Start	End
ENSE00000989461	96383269	96383473
ENSE00000989462	96373375	96373467
ENSE00000989463	96371013	96371137
ENSE00000989464	96364980	96365150
ENSE00000989465	96358993	96359178
ENSE00002156584	96383962	96384761
ENSE00002170563	96387530	96387613
ENSE00002202004	96386254	96386293
ENSE00003814582	96389844	96389912
ENSE00003831146	96352773	96353714

Expression profiles

Bgee: expression breadth ubiquitous, 257 present calls, max score 96.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.3463 / max 473.6693, expressed in 1629 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
121921	11.3711	1616
121920	0.3069	111
121922	0.3044	108
121918	0.2546	118
121919	0.1072	36
206423	0.0020	1

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	96.11	gold quality
cortical plate	UBERON:0005343	95.35	gold quality
corpus callosum	UBERON:0002336	95.04	gold quality
sperm	CL:0000019	94.97	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	94.52	gold quality
cerebellar hemisphere	UBERON:0002245	93.99	gold quality
cerebellar cortex	UBERON:0002129	93.96	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.80	gold quality
oviduct epithelium	UBERON:0004804	93.69	gold quality
tibial nerve	UBERON:0001323	93.57	gold quality
cerebellum	UBERON:0002037	93.56	gold quality
mucosa of stomach	UBERON:0001199	93.39	gold quality
epithelial cell of pancreas	CL:0000083	93.21	gold quality
tendon	UBERON:0000043	93.11	gold quality
right testis	UBERON:0004534	93.07	gold quality
left testis	UBERON:0004533	93.04	gold quality
sural nerve	UBERON:0015488	93.01	gold quality
testis	UBERON:0000473	92.94	gold quality
embryo	UBERON:0000922	92.61	gold quality
ganglionic eminence	UBERON:0004023	92.61	gold quality
ventricular zone	UBERON:0003053	92.51	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.44	gold quality
right lung	UBERON:0002167	92.14	gold quality
spinal cord	UBERON:0002240	91.82	gold quality
metanephros cortex	UBERON:0010533	91.69	gold quality
subcutaneous adipose tissue	UBERON:0002190	91.63	gold quality
tibial artery	UBERON:0007610	91.57	gold quality
popliteal artery	UBERON:0002250	91.55	gold quality
left coronary artery	UBERON:0001626	91.10	gold quality
aorta	UBERON:0000947	91.08	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.93
E-GEOD-81383	no	1325.90
E-MTAB-7303	no	49.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

56 targeting CCDC82, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-8076	99.78	68.52	1170
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-488-3P	99.61	68.79	1731

Literature-anchored findings (GeneRIF, showing 1)

• Genetic diagnosis in Sudanese and Tunisian families with syndromic intellectual disability through exome sequencing. (PMID:35118659)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc82	ENSDARG00000014966
mus_musculus	Ccdc82	ENSMUSG00000079084
rattus_norvegicus	Ccdc82	ENSRNOG00000005713
drosophila_melanogaster	CG17233	FBGN0036958

Protein

Protein identifiers

Coiled-coil domain-containing protein 82 — Q8N4S0 (reviewed: Q8N4S0)

All UniProt accessions (12): Q8N4S0, A0A024R3B8, A0A2R8Y4L3, A0A2R8Y7C3, A0A2R8YE98, A0A7P0T881, A0A7P0T8E7, A0A7P0T8I8, A0A7P0TAG3, A0A7P0TBN6, E9PMD6, F5H777

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N4S0-1	1	yes
Q8N4S0-2	2

RefSeq proteins (4): NP_001305665, NP_001305666, NP_001350523, NP_079001* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR025244	CCDC82	Domain
IPR025451	DUF4211	Domain

Pfam: PF13846, PF13926

UniProt features (22 total): modified residue 7, compositionally biased region 7, sequence variant 3, splice variant 2, chain 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N4S0-F1	64.94	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 88, 131, 154, 195, 219, 227, 329

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 130 (showing top): GCM_ZNF198, GCM_SUFU, BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, CUI_TCF21_TARGETS_2_DN, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP, GCM_PTK2, chr11q21, GCM_RAN, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLACK_UP, MYC_UP.V1_DN, CTTTGCA_MIR527, GUCY1B1_TARGET_GENES, HMGA1_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

418 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC82	GPALPP1	Q8IXQ4	591
CCDC82	LRRC2	Q9BYS8	513
CCDC82	BKGD	Q9H0W9	499
CCDC82	TBC1D22B	Q9NU19	460
CCDC82	RFX5	P48382	436
CCDC82	SLC45A4	Q5BKX6	426
CCDC82	GOLGA8O	A6NCC3	404
CCDC82	ZNF227	Q86WZ6	402
CCDC82	GOLGA8Q	H3BV12	399
CCDC82	FRMD1	Q8N878	396
CCDC82	GOLGA8N	F8WBI6	396
CCDC82	GOLGA8T	H3BQL2	390
CCDC82	TCERG1	O14776	377
CCDC82	CADPS2	Q86UW7	377
CCDC82	SCRN3	Q0VDG4	375

IntAct

19 interactions, top by confidence:

A	B	Type	Score
MARK2	WDR46	psi-mi:“MI:0914”(association)	0.350
Cdc16	ANAPC15	psi-mi:“MI:0914”(association)	0.350
Dynlrb1	DYNC1LI2	psi-mi:“MI:0914”(association)	0.350
MED12	WBP2	psi-mi:“MI:0914”(association)	0.350
NETO2	TIA1	psi-mi:“MI:0914”(association)	0.350
SGF29	TRRAP	psi-mi:“MI:0914”(association)	0.350
COPS7A	BTBD10	psi-mi:“MI:0914”(association)	0.350
Aff1	UVRAG	psi-mi:“MI:0914”(association)	0.350
TINF2	SIRT2	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	RPS3A	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	VWA8	psi-mi:“MI:0914”(association)	0.350
CSNK2B	OSBPL8	psi-mi:“MI:0914”(association)	0.350
RALBP1	AP2A2	psi-mi:“MI:0914”(association)	0.350
SSRP1	DDX39A	psi-mi:“MI:0914”(association)	0.350
SUPT16H	ATRX	psi-mi:“MI:0914”(association)	0.350
CCDC82	ALB	psi-mi:“MI:0914”(association)	0.350
SSRP1	FABP3	psi-mi:“MI:0914”(association)	0.350
VHL	CCDC82	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (55): CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), CCDC82 (Affinity Capture-MS), SERPINB5 (Affinity Capture-MS), PKP3 (Affinity Capture-MS), PKP1 (Affinity Capture-MS), TOMM34 (Affinity Capture-MS), TRIM29 (Affinity Capture-MS), CALML3 (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2L7I0, A0A1L8G2K9, A0A1P8AW69, A5D979, A8K979, B3H578, B4R4H1, D3ZVU1, F4HTH8, F4HXQ7, F4I8S3, F6UH96, G3X912, O64571, P0DKJ8, P62283, P62285, P62286, P62287, P62288, P62289, P62290, P62293, P62294, Q0IGK1, Q2PS26, Q56NI9, Q5QGU6, Q60GC1, Q6DJS0, Q6DRC5, Q6NYJ3, Q6PF04, Q7ZXG4, Q8BMI4, Q8BP27, Q8CIB9, Q8IZT6, Q8N4S0, Q94F87

Diamond homologs: Q66H73, Q6PG04, Q8N4S0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 33 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of TP53 Activity through Phosphorylation	5	23.6×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
DNA repair	5	11.0×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	82
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
986805	NM_024725.4(CCDC82):c.183del (p.Phe61fs)	Pathogenic
1708245	NM_024725.4(CCDC82):c.67C>T (p.Arg23Ter)	Likely pathogenic
3777029	NM_024725.4(CCDC82):c.709C>T (p.Arg237Ter)	Likely pathogenic

SpliceAI

1429 predictions. Top by Δscore:

Variant	Effect	Δscore
11:96353721:A:C	acceptor_gain	1.0000
11:96358988:CTTAC:C	donor_loss	1.0000
11:96358989:TTA:T	donor_loss	1.0000
11:96358991:ACCT:A	donor_gain	1.0000
11:96358992:CCTC:C	donor_gain	1.0000
11:96358994:T:TA	donor_gain	1.0000
11:96359177:ACC:A	acceptor_loss	1.0000
11:96359179:C:CA	acceptor_loss	1.0000
11:96359180:T:C	acceptor_loss	1.0000
11:96371008:TGTA:T	donor_loss	1.0000
11:96371009:GTAC:G	donor_loss	1.0000
11:96371010:TACCT:T	donor_loss	1.0000
11:96371011:A:C	donor_loss	1.0000
11:96371134:CCAT:C	acceptor_gain	1.0000
11:96371135:CAT:C	acceptor_gain	1.0000
11:96371135:CATC:C	acceptor_gain	1.0000
11:96371136:AT:A	acceptor_gain	1.0000
11:96371136:ATCTG:A	acceptor_loss	1.0000
11:96371137:TCTG:T	acceptor_loss	1.0000
11:96371138:C:CC	acceptor_gain	1.0000
11:96371138:C:CG	acceptor_loss	1.0000
11:96371143:C:CT	acceptor_gain	1.0000
11:96371144:A:T	acceptor_gain	1.0000
11:96371149:A:C	acceptor_gain	1.0000
11:96373369:ACTT:A	donor_loss	1.0000
11:96373370:CTT:C	donor_loss	1.0000
11:96373371:TTACC:T	donor_loss	1.0000
11:96373372:TACC:T	donor_loss	1.0000
11:96373373:A:AC	donor_gain	1.0000
11:96373374:C:CC	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000079965 (11:96365614 C>T), RS1000084043 (11:96373671 G>C), RS1000124578 (11:96368711 A>G,T), RS1000439490 (11:96363052 C>T), RS1000491223 (11:96356227 A>C,G), RS1000499268 (11:96385099 T>C), RS1000579293 (11:96369733 A>C), RS1000581360 (11:96380580 A>C,T), RS1000731079 (11:96374510 A>G), RS1000748263 (11:96362796 A>C), RS1000924316 (11:96387014 C>T), RS1001074025 (11:96381062 T>G), RS1001087559 (11:96375003 A>G), RS1001184593 (11:96374748 T>G), RS1001257403 (11:96367414 A>G)

Disease associations

OMIM: gene MIM:619870 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): syndromic intellectual disability (MONDO:0000508), intellectual disability (MONDO:0001071)

Orphanet (2): Rare genetic syndromic intellectual disability (Orphanet:183763), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002077_1	Parkinson’s disease	2.000000e-07
GCST008163_420	Height	2.000000e-06
GCST009391_1026	Metabolite levels	4.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010540	thiamine measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases methylation	4
bisphenol A	decreases expression	2
trichostatin A	affects expression, increases expression	2
sodium arsenite	decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	decreases expression, increases expression	1
methylparaben	decreases expression	1
methacrylaldehyde	affects cotreatment, increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
K 7174	increases expression	1
jinfukang	decreases expression	1
MT19c compound	increases expression	1
Bortezomib	increases expression	1
Sunitinib	increases expression	1
Vorinostat	increases expression	1
Acetaminophen	increases expression	1
Acrolein	affects cotreatment, increases expression	1
Demecolcine	increases expression	1
Estradiol	affects cotreatment, increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Hydrogen Peroxide	affects cotreatment, decreases expression	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders